Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)-Reference-Cited by-同舟云学术

Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)

Published:2015-01-01 Issue:1 Volume:4 Page:1-2
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Lu Lu¹,Xia Shuai¹,Ying Tianlei¹,Jiang Shibo¹

Affiliation:

1. Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

http://www.nature.com/articles/emi201537.pdf

Reference15 articles.

1. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread

2. Calling for rapid development of a safe and effective MERS vaccine

3. HIV-1 inhibition by a peptide

4. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

5. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 1-Phenyl-N-(benzothiazol-2-yl)methanimine derivatives as Middle East respiratory syndrome coronavirus inhibitors;RSC Advances;2020

2. Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV;Antibodies;2019-11-04

3. Study on the 2‐Phenylchroman‐4‐One Derivatives and their anti ‐MERS‐CoV Activities;Bulletin of the Korean Chemical Society;2019-07-28

4. Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4;Viruses;2019-01-14

5. Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD;Viruses;2019-01-06